2. Search Result
Search Result
Results for "

Advanced Glycation End-product (AGE)

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Biochemical Assay Reagents

11

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106024B
    Alagebrium chloride
    1 Publications Verification

    ALT711

    		 Endogenous Metabolite Metabolic Disease
    Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.
    Alagebrium chloride
  • HY-N4089
    Quercetin 3-gentiobioside

    		Aldose Reductase Metabolic Disease
    Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs) .
    Quercetin 3-gentiobioside
  • HY-N4170
    Chebulic acid
    1 Publications Verification

    		 Others Metabolic Disease
    Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity, which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy .
    Chebulic acid
  • HY-B1745
    Pyridoxylamine
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.
    Pyridoxylamine
  • HY-W286743
    Nε-(Carboxymethyl)-L-lysine

    CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine

    		 Biochemical Assay Reagents Cardiovascular Disease Metabolic Disease Cancer
    Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .
    Nε-(Carboxymethyl)-L-lysine
  • HY-B1745A
    Pyridoxylamine dihydrochloride
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .
    Pyridoxylamine dihydrochloride
  • HY-131528
    Tenilsetam

    CAS 997

    		 Others Neurological Disease Metabolic Disease
    Tenilsetam (CAS 997) is an antidementia compound. Tenilsetam is an advanced glycation end product (AGE) inhibitor. Tenilsetam inhibits early retinopathy in experimental diabetes rats .
    Tenilsetam
  • HY-113033A
    Pentosidine TFA

    		Others Neurological Disease
    Pentosidine TFA is a fluorescent advanced glycation end product (AGE) and crosslink. Pentosidine can serve as a biomarker for non-enzymatic modification of long-lived proteins by the Maillard reaction, providing insight into the overall role of the Maillard reaction in aging and disease .
    Pentosidine TFA
  • HY-76383
    LR-90

    		Others Metabolic Disease Inflammation/Immunology
    LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .
    LR-90
  • HY-N7628
    Cassiaside C

    Toralactone 9-O-β-D-gentiobioside

    		 Endogenous Metabolite Metabolic Disease
    Cassiaside C (Toralactone 9-O-β-D-gentiobioside) is a naphthopyrone isolated from the seed of Cassia tora and has inhibitory activity on advanced glycation end products (AGE) formation in vitro .
    Cassiaside C
  • HY-N12071
    Lucidin-ω-Me ether

    		Others Others
    Lucidin-ω-Me ether (Compound 2) can be isolated from the roots of Knoxia valerianoides. Lucidin-ω-Me ether inhibits the advanced glycation end products (AGEs) formation in vitro(IC50: 62.79 μM) .
    Lucidin-ω-Me ether
  • HY-N8375
    Sieboldin

    		Others Metabolic Disease
    Sieboldin is a dihydrochalcone, which inhibits the production of advanced glycation end products (AGE) produced by bovine serum albumins (BSA), has free radical scavenging activity and cytotoxicity in cancer cell lines, and is also used to capture of methylglyoxal (MGO) from Malus baccata .
    Sieboldin
  • HY-14892
    Gemigliptin

    LC15-0444

    		 Dipeptidyl Peptidase Metabolic Disease Cancer
    Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications .
    Gemigliptin
  • HY-N6883
    6-Methoxytricin

    		Aldose Reductase Metabolic Disease
    6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC50 values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .
    6-Methoxytricin
  • HY-14892A
    Gemigliptin tartrate

    LC15-0444 tartrate

    		 Dipeptidyl Peptidase Metabolic Disease
    Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .
    Gemigliptin tartrate
  • HY-N0033
    Poliumoside
    2 Publications Verification

    		 Aldose Reductase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity .
    Poliumoside
  • HY-N7426
    3-Deoxyglucosone

    3-Deoxy-D-glucosone

    		 GLP Receptor Metabolic Disease
    3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes .
    3-Deoxyglucosone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: